Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 12/2019

Open Access 01-12-2019 | Pancreatectomy | Original Article

Nationwide Outcome of Gastrectomy with En-Bloc Partial Pancreatectomy for Gastric Cancer

Authors: L. R. van der Werf, W. J. Eshuis, W. A. Draaisma, B. van Etten, S. S. Gisbertz, E. van der Harst, M. S. L. Liem, V. E. P. P. Lemmens, B. P. L. Wijnhoven, M. G. Besselink, M. I. van Berge Henegouwen, on behalf of the Dutch Upper Gastrointestinal Cancer Audit (DUCA) group.

Published in: Journal of Gastrointestinal Surgery | Issue 12/2019

Login to get access

Abstract

Background

Radical gastrectomy is the cornerstone of the treatment of gastric cancer. For tumors invading the pancreas, en-bloc partial pancreatectomy may be needed for a radical resection. The aim of this study was to evaluate the outcome of gastrectomies with partial pancreatectomy for gastric cancer.

Methods

Patients who underwent gastrectomy with or without partial pancreatectomy for gastric or gastro-oesophageal junction cancer between 2011 and 2015 were selected from the Dutch Upper GI Cancer Audit (DUCA). Outcomes were resection margin (pR0) and Clavien–Dindo grade ≥ III postoperative complications and survival. The association between partial pancreatectomy and postoperative complications was analyzed with multivariable logistic regression. Overall survival of patients with partial pancreatectomy was estimated using the Kaplan–Meier method.

Results

Of 1966 patients that underwent gastrectomy, 55 patients (2.8%) underwent en-bloc partial pancreatectomy. A pR0 resection was achieved in 45 of 55 patients (82% versus 85% in the group without additional resection, P = 0.82). Clavien–Dindo grade ≥ III complications occurred in 21 of 55 patients (38% versus 17%, P < 0.001). Median overall survival [95% confidence interval] was 15 [6.8–23.2] months. For patients with and without perioperative systemic therapy, median survival was 20 [12.3–27.7] and 10 [5.7–14.3] months, and for patients with pR0 and pR1 resection, it was 20 [11.8–28.3] and 5 [2.4–7.6] months, respectively.

Conclusions

Gastrectomy with partial pancreatectomy is not only associated with a pR0 resection rate of 82% but also with increased postoperative morbidity. It should only be performed if a pR0 resection is feasible.
Appendix
Available only for authorised users
Literature
2.
go back to reference Shchepotin IB, Chorny VA, Nauta RJ et al. Extended surgical resection in T4 gastric cancer. Am J Surg 1998; 175: 123–126.CrossRef Shchepotin IB, Chorny VA, Nauta RJ et al. Extended surgical resection in T4 gastric cancer. Am J Surg 1998; 175: 123–126.CrossRef
3.
go back to reference Isozaki H, Tanaka N, Tanigawa N, Okajima K. Prognostic factors in patients with advanced gastric cancer with macroscopic invasion to adjacent organs treated with radical surgery. Gastric Cancer 2000; 3: 202–210.CrossRef Isozaki H, Tanaka N, Tanigawa N, Okajima K. Prognostic factors in patients with advanced gastric cancer with macroscopic invasion to adjacent organs treated with radical surgery. Gastric Cancer 2000; 3: 202–210.CrossRef
4.
go back to reference Csendes A, Burdiles P, Rojas J et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002; 131: 401–407.CrossRef Csendes A, Burdiles P, Rojas J et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002; 131: 401–407.CrossRef
5.
go back to reference Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006; 93: 559–563.CrossRef Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006; 93: 559–563.CrossRef
6.
go back to reference Sano T, Sasako M, Mizusawa J et al. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg 2017; 265: 277–283.CrossRef Sano T, Sasako M, Mizusawa J et al. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg 2017; 265: 277–283.CrossRef
7.
go back to reference Hartgrink HH, Velde CJHvd, Putter H et al. Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial. Journal of Clinical Oncology 2004; 22: 2069–2077.CrossRef Hartgrink HH, Velde CJHvd, Putter H et al. Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial. Journal of Clinical Oncology 2004; 22: 2069–2077.CrossRef
8.
go back to reference Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995–999.PubMed Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995–999.PubMed
9.
go back to reference Bonenkamp JJ, Songun I, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745–748.CrossRef Bonenkamp JJ, Songun I, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745–748.CrossRef
10.
go back to reference Busweiler LA, Wijnhoven BP, van Berge Henegouwen MI et al. Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit. Br J Surg 2016; 103: 1855–1863.CrossRef Busweiler LA, Wijnhoven BP, van Berge Henegouwen MI et al. Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit. Br J Surg 2016; 103: 1855–1863.CrossRef
11.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases 1987; 40: 373–383.CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases 1987; 40: 373–383.CrossRef
12.
go back to reference Bassi C, Dervenis C, Butturini G et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138: 8–13.CrossRef Bassi C, Dervenis C, Butturini G et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138: 8–13.CrossRef
13.
go back to reference Carboni F, Lepiane P, Santoro R et al. Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. J Surg Oncol 2005; 90: 95–100.CrossRef Carboni F, Lepiane P, Santoro R et al. Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. J Surg Oncol 2005; 90: 95–100.CrossRef
14.
go back to reference Jeong O, Choi WY, Park YK. Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs. J Surg Oncol 2009; 100: 115–120.CrossRef Jeong O, Choi WY, Park YK. Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs. J Surg Oncol 2009; 100: 115–120.CrossRef
15.
go back to reference D'Amato A, Santella S, Cristaldi M et al. The role of extended total gastrectomy in advanced gastric cancer. Hepatogastroenterology 2004; 51: 609–612.PubMed D'Amato A, Santella S, Cristaldi M et al. The role of extended total gastrectomy in advanced gastric cancer. Hepatogastroenterology 2004; 51: 609–612.PubMed
16.
go back to reference Saito H, Tsujitani S, Maeda Y et al. Combined resection of invaded organs in patients with T4 gastric carcinoma. Gastric Cancer 2001; 4: 206–211.CrossRef Saito H, Tsujitani S, Maeda Y et al. Combined resection of invaded organs in patients with T4 gastric carcinoma. Gastric Cancer 2001; 4: 206–211.CrossRef
17.
go back to reference Brar SS, Seevaratnam R, Cardoso R et al. Multivisceral resection for gastric cancer: a systematic review. Gastric Cancer 2012; 15: 100–107.CrossRef Brar SS, Seevaratnam R, Cardoso R et al. Multivisceral resection for gastric cancer: a systematic review. Gastric Cancer 2012; 15: 100–107.CrossRef
18.
go back to reference Tran TB, Worhunsky DJ, Norton JA et al. Multivisceral Resection for Gastric Cancer: Results from the US Gastric Cancer Collaborative. Ann Surg Oncol 2015; 22 Suppl 3: S840–847.CrossRef Tran TB, Worhunsky DJ, Norton JA et al. Multivisceral Resection for Gastric Cancer: Results from the US Gastric Cancer Collaborative. Ann Surg Oncol 2015; 22 Suppl 3: S840–847.CrossRef
19.
go back to reference Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol 2007; 25: 2107–2116.CrossRef Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol 2007; 25: 2107–2116.CrossRef
20.
go back to reference Beck N, Busweiler LAD, Schouwenburg MG et al. Factors contributing to variation in the use of multimodality treatment in patients with gastric cancer: A Dutch population based study. Eur J Surg Oncol 2018; 44: 260–267.CrossRef Beck N, Busweiler LAD, Schouwenburg MG et al. Factors contributing to variation in the use of multimodality treatment in patients with gastric cancer: A Dutch population based study. Eur J Surg Oncol 2018; 44: 260–267.CrossRef
21.
go back to reference Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20.CrossRef Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20.CrossRef
22.
go back to reference Schouwenburg MG, Busweiler LAD, Beck N et al. Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit. Eur J Surg Oncol 2018. Schouwenburg MG, Busweiler LAD, Beck N et al. Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit. Eur J Surg Oncol 2018.
23.
go back to reference Slagter AE, Jansen EPM, van Laarhoven HWM et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer 2018; 18: 877.CrossRef Slagter AE, Jansen EPM, van Laarhoven HWM et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer 2018; 18: 877.CrossRef
24.
go back to reference Martin RC, 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 2002; 236: 159–165.CrossRef Martin RC, 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 2002; 236: 159–165.CrossRef
25.
go back to reference van Rijssen LB, Koerkamp BG, Zwart MJ et al. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. HPB (Oxford) 2017; 19: 919–926.CrossRef van Rijssen LB, Koerkamp BG, Zwart MJ et al. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. HPB (Oxford) 2017; 19: 919–926.CrossRef
26.
go back to reference Mita K, Ito H, Katsube T et al. Prognostic Factors Affecting Survival After Multivisceral Resection in Patients with Clinical T4b Gastric Cancer. J Gastrointest Surg 2017; 21: 1993–1999.CrossRef Mita K, Ito H, Katsube T et al. Prognostic Factors Affecting Survival After Multivisceral Resection in Patients with Clinical T4b Gastric Cancer. J Gastrointest Surg 2017; 21: 1993–1999.CrossRef
27.
go back to reference Cheng CT, Tsai CY, Hsu JT et al. Aggressive surgical approach for patients with T4 gastric carcinoma: promise or myth? Ann Surg Oncol 2011; 18: 1606–1614.CrossRef Cheng CT, Tsai CY, Hsu JT et al. Aggressive surgical approach for patients with T4 gastric carcinoma: promise or myth? Ann Surg Oncol 2011; 18: 1606–1614.CrossRef
28.
go back to reference van Putten M, Verhoeven RH, van Sandick JW et al. Hospital of diagnosis and probability of having surgical treatment for resectable gastric cancer. Br J Surg 2016; 103: 233–241.CrossRef van Putten M, Verhoeven RH, van Sandick JW et al. Hospital of diagnosis and probability of having surgical treatment for resectable gastric cancer. Br J Surg 2016; 103: 233–241.CrossRef
Metadata
Title
Nationwide Outcome of Gastrectomy with En-Bloc Partial Pancreatectomy for Gastric Cancer
Authors
L. R. van der Werf
W. J. Eshuis
W. A. Draaisma
B. van Etten
S. S. Gisbertz
E. van der Harst
M. S. L. Liem
V. E. P. P. Lemmens
B. P. L. Wijnhoven
M. G. Besselink
M. I. van Berge Henegouwen
on behalf of the Dutch Upper Gastrointestinal Cancer Audit (DUCA) group.
Publication date
01-12-2019
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 12/2019
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04133-z

Other articles of this Issue 12/2019

Journal of Gastrointestinal Surgery 12/2019 Go to the issue